Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Gastroenterology - 1 Nov 2011

Wong Banny S, Camilleri Michael, Busciglio Irene, Carlson Paula, Szarka Lawrence A, Burton Duane, Zinsmeister Alan R

Abstract excerpt

BACKGROUND & AIMS: Cannabinoid receptors are located on cholinergic neurons. Genetic variants that affect endocannabinoid metabolism are associated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea. We compared the effects of dronabinol, a nonselective agonist of the cannabinoid receptor, with those of placebo on colonic motility and sensation in patients with IBS, and examined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Colon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Double-Blind Method

Share to Fasting

Share to Gastrointestinal Motility

Share to Irritable Bowel Syndrome

Share to Patient Compliance

Source

Open in PubMed Open full text

Identifiers

PMID: 21803011
DOI: 10.1053/j.gastro.2011.07.036
PMCID: PMC3202649

Genes

FAAH
CNR1
MGLL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.PMID 21803011Read ↗

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.Semantic proximity Read ↗

Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.Semantic proximity Read ↗

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.Semantic proximity Read ↗

Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits.Semantic proximity Read ↗

Cannabinoids and the gut: new developments and emerging concepts.Semantic proximity Read ↗

Pharmacogenetics and the Treatment of Functional Gastrointestinal DisordersSemantic proximity Read ↗

Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome.Semantic proximity Read ↗

Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentSemantic proximity Read ↗

Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?Semantic proximity Read ↗

Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders.Semantic proximity Read ↗

Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.Semantic proximity Read ↗

The LHA–DMV GABAergic Pathway Drives Constipation-predominant Irritable Bowel Syndrome via Modulating Colonic TRPV4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.